Ananthan Sadagopan

The paper identifies BCL-XL dependence as a common vulnerability in various kidney cancer subtypes and develops a model to predict it using biomarkers like AMPK activation.

This paper identifies a bifunctional small molecule that can induce both transactivation and repression of gene expression depending on cellular context.

This paper introduces GRIPs, a scalable platform for PTM editing using chimeric molecules, demonstrating functionality in multiple systems and confirming specificity through proteomics.

This paper detects and monitors translocation renal cell carcinoma (tRCC) using plasma cell-free epigenomic profiling, achieving high accuracy in distinguishing tRCC from other cancers and healthy controls.

The paper shows that p53 protein abundance in TP53 mutant cancers can be exploited to selectively kill these cells using proximity-inducing small molecules.

This study identifies CDK4/6 and mTORC1 pathway activation in tRCC and shows that their dual inhibition synergistically suppresses tRCC cell growth in vitro and xenografts in vivo.

This study identifies TFE3 fusions driving OXPHOS in tRCC and reveals EGLN1 inhibition as a therapeutic target.

This study uses machine learning to infer gene dependencies from tumor transcriptomes, identifying cancer vulnerabilities in rare cancers without experimental screening.